| Date | Title | Description | |
|---|---|---|---|
| 25 Feb 2026 | On P&L | The Company releases the full year 2025 financial results presentation. | Download |
| 25 Feb 2026 | About Corporate Governance | The Company informs about the agreements adopted by the Board of Directors. | Download |
| 06 Nov 2025 | On P&L | The Company releases the press release related to the first nine months of 2025 financial results | Download |
| 06 Nov 2025 | On P&L | The Company releases the first nine months of 2025 financial results presentation | Download |
| 21 Oct 2025 | On business and financial situation | The Company releases the press release in relation to the announcement of the collaboration with Roche for the manufacture of a new medicine in development | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 03 Nov 2021 | On business and financial situation | The Company releases the press release related to the first nine months 2021 financial results | Download |
| 03 Nov 2021 | On business and financial situation | The Company releases the first nine months 2021 financial results presentation | Download |
| 21 Oct 2021 | Liquidity and counterparty agreements | Download | |
| 21 Oct 2021 | On business and financial situation | The Company informs of the delay in the decision on Risperidone ISM® by the U.S. Food and Drug Administration (“FDA”). | Download |
| 07 Oct 2021 | Liquidity and counterparty agreements | Download |